2021
DOI: 10.1007/s11033-021-06981-y
|View full text |Cite
|
Sign up to set email alerts
|

The regulatory effects of clomiphene and tamoxifen on mTOR and LC3-II expressions in relation to autophagy in experimental polycystic ovary syndrome (PCOS)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 49 publications
0
2
0
Order By: Relevance
“…Because bazedoxifene treatment stimulates LC3B vesicles production in LGMD R2 muscular cells and because LC3-II vesicles might be recruited to the damaged membrane site for membrane resealing process (Corkery et al, 2023), we hypothesized that its widespread protective effect might therefore be linked to this effect on autophagy rather than to the clearance of protein aggregates. This hypothesis is also supported by the fact that bazedoxifene belongs to the same class of drugs as tamoxifen, reported to improve muscle contractility in preclinical models of centronuclear myopathies (Gineste et al, 2023;Gayi et al, 2018b) and currently investigated in a phase 3 clinical trial to treat Duchenne muscular dystrophie (NCT03354039) (Gayi et al, 2018a;Dorchies et al, 2013;Nagy et al, 2019;Birnbaum et al, 2022;Kuşçu et al, 2022).…”
Section: Discussionmentioning
confidence: 90%
“…Because bazedoxifene treatment stimulates LC3B vesicles production in LGMD R2 muscular cells and because LC3-II vesicles might be recruited to the damaged membrane site for membrane resealing process (Corkery et al, 2023), we hypothesized that its widespread protective effect might therefore be linked to this effect on autophagy rather than to the clearance of protein aggregates. This hypothesis is also supported by the fact that bazedoxifene belongs to the same class of drugs as tamoxifen, reported to improve muscle contractility in preclinical models of centronuclear myopathies (Gineste et al, 2023;Gayi et al, 2018b) and currently investigated in a phase 3 clinical trial to treat Duchenne muscular dystrophie (NCT03354039) (Gayi et al, 2018a;Dorchies et al, 2013;Nagy et al, 2019;Birnbaum et al, 2022;Kuşçu et al, 2022).…”
Section: Discussionmentioning
confidence: 90%
“…The present study revealed that the expression of the structural protein Desmin increased in a time-dependent manner when exposed to cadmium, indicating that MPC5 cells were damaged [ 48 , 49 ]. LC3 is a marker of cellular autophagy, and the amount of LC3-II was positively correlated with the degree of autophagy occurring [ 50 ]. The present study showed that the expression of LC3-II, a functional protein of autophagy, increased in a time-dependent manner after cadmium treatment, and the degree of autophagy was severe.…”
Section: Discussionmentioning
confidence: 99%